BioSpace News Archive

The approval marks Emgality as the first calcitonin gene-related peptide (CGRP) antibody to be approved for two distinct headache disorders.

EpimAb plans to use the funds to advance its Phase I/II clinical program, EMB01, expand its clinical pipeline into immuno-oncology and other areas and add a new manufacturing site in Suzhou for process development and pilot manufacturing.

The Oregon Bioscience Association recently released a new economic impact report, showing that the state’s biopharma and life science industry is continuing to grow at a significant clip.

Recently released documents indicate that Pfizer spent three years reviewing whether the science supported running a trial on Enbrel in Alzheimer’s.

ASCO called rare cancer treatments the “advance of the year” in oncology.

Hundreds lose their jobs as companies close facilities and shift business focuses.

Heidelberg Pharma AG announced that it has received a milestone payment of 250 TUSD from its cooperation partner Telix Pharmaceuticals Limited, Melbourne, Australia,.

InflaRx reported the top-line results of the international SHINE Phase IIb study, investigating the safety and efficacy of IFX-1, a first-in-class anti-human complement factor C5a monoclonal antibody, in patients suffering from moderate to severe Hidradenitis Suppurativa (HS), a painful and debilitating chronic inflammatory skin disease with limited treatment options.

The researchers, in analyzing more than 400,000 genomes and associated health records, found that individuals with two mutated copies of the CCR5 gene, the one He Jiankui modified, had a significantly higher death rate between the ages 41 and 78 than people with one or no copies.

The alliance will catalyze the development of novel therapeutics coming from the research labs of Columbia University and accelerate these discoveries toward clinical validation in patients.